DaVita Inc. (NYSE:DVA) Stake Lessened by ExodusPoint Capital Management LP

ExodusPoint Capital Management LP trimmed its stake in shares of DaVita Inc. (NYSE:DVA) by 39.3% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 36,117 shares of the company’s stock after selling 23,399 shares during the quarter. ExodusPoint Capital Management LP’s holdings in DaVita were worth $5,401,000 at the end of the most recent quarter.

Other hedge funds also recently added to or reduced their stakes in the company. Franklin Resources Inc. lifted its position in shares of DaVita by 134.6% during the third quarter. Franklin Resources Inc. now owns 54,901 shares of the company’s stock worth $8,885,000 after purchasing an additional 31,502 shares during the last quarter. FMR LLC lifted its holdings in DaVita by 659.9% during the 3rd quarter. FMR LLC now owns 177,406 shares of the company’s stock worth $29,082,000 after buying an additional 154,061 shares during the last quarter. Assenagon Asset Management S.A. grew its position in shares of DaVita by 201.7% in the 4th quarter. Assenagon Asset Management S.A. now owns 74,617 shares of the company’s stock worth $11,159,000 after acquiring an additional 49,885 shares in the last quarter. Neo Ivy Capital Management acquired a new position in shares of DaVita in the 3rd quarter worth approximately $726,000. Finally, Hussman Strategic Advisors Inc. increased its holdings in shares of DaVita by 200.0% in the 4th quarter. Hussman Strategic Advisors Inc. now owns 25,200 shares of the company’s stock valued at $3,769,000 after acquiring an additional 16,800 shares during the last quarter. 90.12% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of equities analysts have commented on the stock. Sanford C. Bernstein set a $184.00 price objective on shares of DaVita in a report on Friday, February 21st. Barclays raised their price target on shares of DaVita from $164.00 to $169.00 and gave the stock an “equal weight” rating in a research report on Tuesday, February 18th. Cowen reaffirmed a “hold” rating on shares of DaVita in a research report on Tuesday, February 18th. Finally, StockNews.com cut shares of DaVita from a “buy” rating to a “hold” rating in a report on Wednesday. One investment analyst has rated the stock with a sell rating, five have assigned a hold rating and one has issued a buy rating to the company. According to MarketBeat.com, DaVita currently has an average rating of “Hold” and a consensus target price of $166.33.

DaVita Stock Performance

DVA stock opened at $149.37 on Friday. The stock’s fifty day moving average is $155.75 and its two-hundred day moving average is $157.23. The stock has a market capitalization of $11.95 billion, a price-to-earnings ratio of 13.91, a PEG ratio of 1.07 and a beta of 1.04. The company has a debt-to-equity ratio of 23.18, a quick ratio of 1.21 and a current ratio of 1.26. DaVita Inc. has a 1 year low of $125.64 and a 1 year high of $179.60.

DaVita (NYSE:DVA) last posted its earnings results on Thursday, February 13th. The company reported $2.24 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.14 by $0.10. DaVita had a net margin of 7.31% and a return on equity of 115.48%. On average, research analysts predict that DaVita Inc. will post 10.76 EPS for the current year.

About DaVita

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.